{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:20:58Z","timestamp":1775694058731,"version":"3.50.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,3,19]],"date-time":"2022-03-19T00:00:00Z","timestamp":1647648000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,3,19]],"date-time":"2022-03-19T00:00:00Z","timestamp":1647648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-022-00814-3","type":"journal-article","created":{"date-parts":[[2022,3,19]],"date-time":"2022-03-19T01:03:46Z","timestamp":1647651826000},"page":"245-254","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Cyclin-dependent kinase 4 and 6 inhibitors in combination with neoadjuvant endocrine therapy in estrogen receptor-positive early breast cancer: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"23","author":[{"given":"Yumei","family":"Guan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guoshuang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianqian","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanfang","family":"Xin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingfa","family":"Huo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinming","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuxing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dengfeng","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zitao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1266-8943","authenticated-orcid":false,"given":"Jiuda","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,19]]},"reference":[{"key":"814_CR1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries. CA Cancer J Clin. 2021. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"814_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s10549-018-4901-0","volume":"172","author":"C Messina","year":"2018","unstructured":"Messina C, Cattrini C, Buzzatti G, et al. CDK4\/6 inhibitors in advanced hormone receptor-positive\/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials. Breast Cancer Res Treat. 2018;172(1):9\u201321. https:\/\/doi.org\/10.1007\/s10549-018-4901-0.","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"814_CR3","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1080\/03007995.2018.1479246","volume":"34","author":"R Ayyagari","year":"2018","unstructured":"Ayyagari R, Tang D, Patterson-Lomba O, et al. Progression-free survival with endocrine-based therapies following progression on non-steroidal aromatase inhibitor among postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative metastatic breast cancer: a network meta-analysis. Curr Med Res Opin. 2018;34(9):1645\u201352. https:\/\/doi.org\/10.1080\/03007995.2018.1479246.","journal-title":"Curr Med Res Opin"},{"issue":"18","key":"814_CR4","doi-asserted-by":"publisher","first-page":"3342","DOI":"10.1016\/j.ejca.2012.05.023","volume":"48","author":"N Houssami","year":"2012","unstructured":"Houssami N, Macaskill P, von Minckwitz G, et al. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer. 2012;48(18):3342\u201354. https:\/\/doi.org\/10.1016\/j.ejca.2012.05.023.","journal-title":"Eur J Cancer"},{"issue":"12","key":"814_CR5","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1093\/annonc\/mds132","volume":"23","author":"E Alba","year":"2012","unstructured":"Alba E, Calvo L, Albanell J, et al. Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM\/2006-03, a multicenter, randomized, phase-II study. Ann Oncol. 2012;23(12):3069\u201374. https:\/\/doi.org\/10.1093\/annonc\/mds132.","journal-title":"Ann Oncol"},{"issue":"8","key":"814_CR6","doi-asserted-by":"publisher","first-page":"12393","DOI":"10.1002\/jcp.28068","volume":"234","author":"T Zhang","year":"2019","unstructured":"Zhang T, Feng F, Yao Y, et al. Efficacy and acceptability of neoadjuvant endocrine therapy in patients with hormone receptor- positive breast cancer: a network meta- analysis. J Cell Physiol. 2019;234(8):12393\u2013403. https:\/\/doi.org\/10.1002\/jcp.28068.","journal-title":"J Cell Physiol"},{"issue":"11","key":"814_CR7","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1001\/jamaoncol.2016.1897","volume":"2","author":"LM Spring","year":"2016","unstructured":"Spring LM, Gupta A, Reynolds KL, et al. Neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer: a systematic review and meta-analysis. JAMA Oncol. 2016;2(11):1477. https:\/\/doi.org\/10.1001\/jamaoncol.2016.1897.","journal-title":"JAMA Oncol"},{"issue":"1","key":"814_CR8","doi-asserted-by":"publisher","first-page":"77","DOI":"10.6004\/jnccn.2021.0001","volume":"19","author":"MB Daly","year":"2021","unstructured":"Daly MB, Pal T, Berry MP, et al. Genetic\/familial high-risk assessment: breast, ovarian, and pancreatic, version 2 2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(1):77\u2013102. https:\/\/doi.org\/10.6004\/jnccn.2021.0001.","journal-title":"J Natl Compr Canc Netw"},{"issue":"18","key":"814_CR9","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","volume":"375","author":"GN Hortobagyi","year":"2016","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375(18):1738\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1609709.","journal-title":"N Engl J Med"},{"issue":"4","key":"814_CR10","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1158\/2159-8290.CD-11-0101","volume":"1","author":"TW Miller","year":"2011","unstructured":"Miller TW, Balko JM, Fox EM, et al. ER\u03b1-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. Cancer Discov. 2011;1(4):338\u201351. https:\/\/doi.org\/10.1158\/2159-8290.CD-11-0101.","journal-title":"Cancer Discov"},{"issue":"25","key":"814_CR11","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1200\/JCO.2016.67.3061","volume":"34","author":"C Fribbens","year":"2016","unstructured":"Fribbens C, O\u2019Leary B, Kilburn L, et al. Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer. J Clin Oncol. 2016;34(25):2961\u20138. https:\/\/doi.org\/10.1200\/JCO.2016.67.3061.","journal-title":"J Clin Oncol"},{"issue":"22","key":"814_CR12","doi-asserted-by":"publisher","first-page":"5121","DOI":"10.1158\/1078-0432.CCR-15-0360","volume":"21","author":"SE Wardell","year":"2015","unstructured":"Wardell SE, Ellis MJ, Alley HM, et al. Efficacy of SERD\/SERM Hybrid-CDK4\/6 inhibitor combinations in models of endocrine therapy\u2013resistant breast cancer. Clin Cancer Res. 2015;21(22):5121\u2013513. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-0360.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"814_CR13","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrc3920","volume":"15","author":"CX Ma","year":"2015","unstructured":"Ma CX, Reinert T, Chmielewska I, et al. Mechanisms of aromatase inhibitor resistance. Nat Rev Cancer. 2015;15(5):261\u201375. https:\/\/doi.org\/10.1038\/nrc3920.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"814_CR14","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nrc2602","volume":"9","author":"M Malumbres","year":"2009","unstructured":"Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009;9(3):153\u201366. https:\/\/doi.org\/10.1038\/nrc2602.","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"814_CR15","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/nrm3629","volume":"14","author":"C Bertoli","year":"2013","unstructured":"Bertoli C, Skotheim JM, de Bruin RAM. Control of cell cycle transcription during G1 and S phases. Nature Rev Mol Cell Biol. 2013;14(8):518\u201328. https:\/\/doi.org\/10.1038\/nrm3629.","journal-title":"Nature Rev Mol Cell Biol."},{"issue":"1","key":"814_CR16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13058-015-0661-5","volume":"18","author":"RS Finn","year":"2016","unstructured":"Finn RS, Aleshin A, Slamon DJ. Targeting the cyclin-dependent kinases (CDK) 4\/6 in estrogen receptor-positive breast cancers. Breast Cancer Res. 2016;18(1):17. https:\/\/doi.org\/10.1186\/s13058-015-0661-5.","journal-title":"Breast Cancer Res"},{"issue":"11","key":"814_CR17","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1177\/2042098617722516","volume":"8","author":"KS Shohdy","year":"2017","unstructured":"Shohdy KS, Lasheen S, Kassem L, et al. Gastrointestinal adverse effects of cyclin-dependent kinase 4 and 6 inhibitors in breast cancer patients: a systematic review and meta-analysis. Therapeut Adv Drug Saf. 2017;8(11):337\u201347. https:\/\/doi.org\/10.1177\/2042098617722516.","journal-title":"Therapeut Adv Drug Saf"},{"issue":"2","key":"814_CR18","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s11523-019-00633-9","volume":"14","author":"Q Guo","year":"2019","unstructured":"Guo Q, Lin X, Ye L, et al. Comparative efficacy of CDK4\/6 inhibitors plus aromatase inhibitors versus fulvestrant for the first-line treatment of hormone receptor-positive advanced breast cancer: a network meta-analysis. Target Oncol. 2019;14(2):139\u201348. https:\/\/doi.org\/10.1007\/s11523-019-00633-9.","journal-title":"Target Oncol"},{"issue":"8","key":"814_CR19","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/nrc3090","volume":"11","author":"EA Musgrove","year":"2011","unstructured":"Musgrove EA, Elizabeth Caldon C, Barraclough J, et al. Cyclin D as a therapeutic target in cancer. Nat Rev Cancer. 2011;11(8):558\u201372. https:\/\/doi.org\/10.1038\/nrc3090.","journal-title":"Nat Rev Cancer"},{"key":"814_CR20","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.breast.2016.06.008","volume":"28","author":"G Curigliano","year":"2016","unstructured":"Curigliano G, G\u00f3mez Pardo P, Meric-Bernstam F, et al. Ribociclib plus letrozole in early breast cancer: a presurgical, window-of opportunity study. The Breast. 2016;28:191\u20138. https:\/\/doi.org\/10.1016\/j.breast.2016.06.008.","journal-title":"The Breast"},{"issue":"1","key":"814_CR21","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S1470-2045(19)30786-7","volume":"21","author":"A Prat","year":"2020","unstructured":"Prat A, Saura C, Pascual T, et al. Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2020;21(1):33\u201343. https:\/\/doi.org\/10.1016\/S1470-2045(19)30786-7.","journal-title":"Lancet Oncol"},{"issue":"3","key":"814_CR22","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1158\/1078-0432.CCR-19-1425","volume":"26","author":"SA Hurvitz","year":"2020","unstructured":"Hurvitz SA, Martin M, Press MF, et al. Potent cell-cycle inhibition and upregulation of immune response with abemaciclib and Anastrozole in neoMONARCH, Phase II neoadjuvant study in HR +\/HER2- breast cancer. Clin Cancer Res. 2020;26(3):566\u201380. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1425.","journal-title":"Clin Cancer Res"},{"issue":"15_suppl","key":"814_CR23","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1200\/JCO.2020.38.15_suppl.505","volume":"38","author":"QJ Khan","year":"2021","unstructured":"Khan QJ, O\u2019Dea A, Bardia A, et al. Letrozole + ribociclib versus letrozole + placebo as neoadjuvant therapy for ER+ breast cancer (FELINE trial). J Clin Oncol. 2021;38(15_suppl):505\u2013505. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.505.","journal-title":"J Clin Oncol"},{"issue":"12","key":"814_CR24","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1093\/annonc\/mdy448","volume":"29","author":"P Cottu","year":"2018","unstructured":"Cottu P, D\u2019Hondt V, Dureau S, et al. Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer. Ann Oncol. 2018;29(12):2334\u201340. https:\/\/doi.org\/10.1093\/annonc\/mdy448.","journal-title":"Ann Oncol"},{"issue":"3","key":"814_CR25","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1200\/JCO.18.01624","volume":"37","author":"S Johnston","year":"2019","unstructured":"Johnston S, Puhalla S, Wheatley D, et al. Randomized phase II study evaluating palbociclib in addition to letrozole as neoadjuvant therapy in estrogen receptor-positive early breast cancer: PALLET trial. JCO. 2019;37(3):178\u201389. https:\/\/doi.org\/10.1200\/JCO.18.01624.","journal-title":"JCO"},{"issue":"15","key":"814_CR26","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1158\/1078-0432","volume":"23","author":"CX Ma","year":"2017","unstructured":"Ma CX, Gao F, Luo J, et al. NeoPalAna: neoadjuvant palbociclib, a cyclin-dependent kinase 4\/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor-positive breast cancer. Clin Cancer Res. 2017;23(15):4055\u201365. https:\/\/doi.org\/10.1158\/1078-0432.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"814_CR27","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1530\/ERC-17-0396","volume":"25","author":"LWC Chow","year":"2018","unstructured":"Chow LWC, Morita S, Chow CYC, et al. Neoadjuvant palbociclib on ER+ breast cancer (N007): clinical response and EndoPredict\u2019s value. Endocr Relat Cancer. 2018;25(2):123\u201330. https:\/\/doi.org\/10.1530\/ERC-17-0396.","journal-title":"Endocr Relat Cancer"},{"key":"814_CR28","doi-asserted-by":"publisher","first-page":"S1285","DOI":"10.1016\/j.annonc.2021.08.2086","volume":"32","author":"SA Hurvitz","year":"2021","unstructured":"Hurvitz SA, Park YH, Bardia A, et al. LBA14 Neoadjuvant giredestrant (GDC-9545)+ palbociclib (palbo) vs anastrozole (A)+ palbo in post-menopausal women with oestrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+\/HER2\u2013eBC): Interim analysis of the randomised, open-label, phase II coopERA BC study. Ann Oncol. 2021;32:S1285\u20136. https:\/\/doi.org\/10.1016\/j.annonc.2021.08.2086.","journal-title":"Ann Oncol"},{"key":"814_CR29","doi-asserted-by":"publisher","unstructured":"Ciapponi A. La declaraci\u00f3n PRISMA 2020: una gu\u00eda actualizada para reportar revisiones sistem\u00e1ticas. Evidencia, actualizacion en la pr\u00e1ctica ambulatoria 24(3): e002139-e002139. https:\/\/doi.org\/10.51987\/evidencia.v24i4.6960","DOI":"10.51987\/evidencia.v24i4.6960"},{"issue":"4","key":"814_CR30","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1093\/jnci\/22.4.719","volume":"22","author":"N Mantel","year":"1959","unstructured":"Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719\u201348. https:\/\/doi.org\/10.1093\/jnci\/22.4.719.","journal-title":"J Natl Cancer Inst"},{"issue":"7414","key":"814_CR31","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360. https:\/\/doi.org\/10.1136\/bmj.327.7414.557.","journal-title":"BMJ"},{"issue":"2","key":"814_CR32","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/gepi.20048","volume":"28","author":"E Zintzaras","year":"2005","unstructured":"Zintzaras E, Ioannidis JP. Heterogeneity testing in meta- analysis of genome searches. Genet Epidemiol. 2005;28(2):123\u201337. https:\/\/doi.org\/10.1002\/gepi.20048.","journal-title":"Genet Epidemiol"},{"issue":"3","key":"814_CR33","doi-asserted-by":"publisher","first-page":"458","DOI":"10.3390\/cancers13030458","volume":"13","author":"N Dey","year":"2021","unstructured":"Dey N, Aske J, De P. Targeted neoadjuvant therapies in HR+\/HER2\u2014breast cancers: challenges for improving pCR. Cancers. 2021;13(3):458. https:\/\/doi.org\/10.3390\/cancers13030458.","journal-title":"Cancers"},{"issue":"10","key":"814_CR34","doi-asserted-by":"publisher","first-page":"e2020312","DOI":"10.1001\/jamanetworkopen.2020.20312","volume":"3","author":"J Li","year":"2020","unstructured":"Li J, Huo X, Zhao F, et al. Association of cyclin-dependent kinases 4 and 6 inhibitors with survival in patients with hormone receptor-positive metastatic breast cancer: a systematic review and meta-analysis. JAMA Netw Open. 2020;3(10):e2020312\u2013e2020312. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.20312.","journal-title":"JAMA Netw Open"},{"issue":"2","key":"814_CR35","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S1470-2045(18)30001-9","volume":"19","author":"L Gianni","year":"2018","unstructured":"Gianni L, Bisagni G, Colleoni M, et al. Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NAPHER2): an exploratory, open-label, phase 2 study. Lancet Oncol. 2018;19(2):249\u201356. https:\/\/doi.org\/10.1016\/S1470-2045(18)30001-9.","journal-title":"Lancet Oncol"},{"issue":"12","key":"814_CR36","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1093\/annonc\/mdy456","volume":"29","author":"M Brandao","year":"2018","unstructured":"Brandao M, Ignatiadis M. CDK4\/6 inhibitors as neoadjuvant treatment in breast cancer-what can we learn? Ann Oncol. 2018;29(12):2274\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdy456.","journal-title":"Ann Oncol"},{"issue":"6","key":"814_CR37","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.3390\/cancers13061458","volume":"13","author":"F Schettini","year":"2021","unstructured":"Schettini F, Giuliano M, Giudici F, et al. Endocrine-based treatments in clinically-relevant subgroups of hormone receptor Positive\/HER2-negative metastatic breast cancer: systematic review and meta analysis. Cancers. 2021;13(6):1458. https:\/\/doi.org\/10.3390\/cancers13061458.","journal-title":"Cancers"},{"key":"814_CR38","doi-asserted-by":"publisher","first-page":"S104","DOI":"10.1016\/j.breast.2017.06.039","volume":"34","author":"MJ Ellis","year":"2017","unstructured":"Ellis MJ. Lessons in precision oncology from neoadjuvant endocrine therapy trials in ER+ breast cancer. The Breast. 2017;34:S104\u20137. https:\/\/doi.org\/10.1016\/j.breast.2017.06.039.","journal-title":"The Breast"},{"issue":"22","key":"814_CR39","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1093\/jnci\/djr393","volume":"103","author":"M Dowsett","year":"2011","unstructured":"Dowsett M, Nielsen TO, A\u2019Hern R, et al. Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group. JNCI: J Natl Cancer Inst. 2011;103(22):1656\u201364. https:\/\/doi.org\/10.1093\/jnci\/djr393.","journal-title":"JNCI: J Natl Cancer Inst."},{"issue":"11","key":"814_CR40","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/S1470-2045(20)30458-7","volume":"21","author":"I Smith","year":"2020","unstructured":"Smith I, Robertson J, Kilburn L, et al. Long term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial. Lancet Oncol. 2020;21(11):1443\u201354. https:\/\/doi.org\/10.1016\/S1470-2045(20)30458-7.","journal-title":"Lancet Oncol"},{"issue":"9","key":"814_CR41","doi-asserted-by":"publisher","first-page":"843","DOI":"10.2217\/fon-2016-0420","volume":"13","author":"X Chen","year":"2017","unstructured":"Chen X, He C, Han D, et al. The predictive value of Ki-67 before neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis. Future Oncol. 2017;13(9):843\u201357. https:\/\/doi.org\/10.2217\/fon-2016-0420.","journal-title":"Future Oncol"},{"issue":"11","key":"814_CR42","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.2217\/fon-2016-0428","volume":"13","author":"L Li","year":"2017","unstructured":"Li L, Han D, Wang X, et al. Prognostic values of Ki-67 in neoadjuvant setting for breast cancer: a systematic review and meta-analysis. Future Oncol. 2017;13(11):1021\u201334. https:\/\/doi.org\/10.2217\/fon-2016-0428.","journal-title":"Future Oncol"},{"issue":"51","key":"814_CR43","doi-asserted-by":"publisher","first-page":"e9384","DOI":"10.1097\/MD.0000000000009384","volume":"96","author":"M Tao","year":"2017","unstructured":"Tao M, Chen S, Zhang X, et al. Ki-67 labeling index is a predictive marker for a pathological complete response to neoadjuvant chemotherapy in breast cancer: a meta-analysis. Medicine. 2017;96(51):e9384. https:\/\/doi.org\/10.1097\/MD.0000000000009384.","journal-title":"Medicine"},{"issue":"1","key":"814_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13000-017-0608-5","volume":"12","author":"B \u00c1cs","year":"2017","unstructured":"\u00c1cs B, Z\u00e1mb\u00f3 V, V\u00edzkeleti L, et al. Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy. Diagn Pathol. 2017;12(1):1\u201312. https:\/\/doi.org\/10.1186\/s13000-017-0608-5.","journal-title":"Diagn Pathol"},{"issue":"6","key":"814_CR45","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1097\/CCO.0000000000000401","volume":"29","author":"C Criscitiello","year":"2017","unstructured":"Criscitiello C, Viale G, Curigliano G. Extending indication of cyclin-dependent kinase 4\/6 inhibitors in the adjuvant and neoadjuvant setting. Curr Opin Oncol. 2017;29(6):428\u201333. https:\/\/doi.org\/10.1097\/CCO.0000000000000401.","journal-title":"Curr Opin Oncol"},{"issue":"6","key":"814_CR46","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.clbc.2019.05.019","volume":"19","author":"L Rossi","year":"2019","unstructured":"Rossi L, McCartney A, Risi E, et al. Cyclin-22 dependent kinase 4\/6 inhibitors in neoadjuvant endocrine therapy of hormone receptor positive breast Cancer. Clin Breast Cancer. 2019;19(6):392\u20138. https:\/\/doi.org\/10.1016\/j.clbc.2019.05.019.","journal-title":"Clin Breast Cancer"},{"issue":"2","key":"814_CR47","doi-asserted-by":"publisher","first-page":"167e70","DOI":"10.1093\/jnci\/djk020","volume":"99","author":"M Dowsett","year":"2017","unstructured":"Dowsett M, Smith IE, Ebbs SR, et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst. 2017;99(2):167e70. https:\/\/doi.org\/10.1093\/jnci\/djk020.","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"814_CR48","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.jamcollsurg.2009.01.035","volume":"208","author":"JA Olson","year":"2009","unstructured":"Olson JA, Thomas G, Carey LA, et al. Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial. J Am Coll Surg. 2009;208(5):906\u201314. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2009.01.035.","journal-title":"J Am Coll Surg"},{"issue":"5","key":"814_CR49","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1634\/theoncologist.2014-0443","volume":"20","author":"CG Murphy","year":"2015","unstructured":"Murphy CG, Dicklerb MN. The Role of CDK4\/6 inhibition in breast cancer. Oncologist. 2015;20(5):483\u201390. https:\/\/doi.org\/10.1634\/theoncologist.2014-0443.","journal-title":"Oncologist"},{"issue":"1","key":"814_CR50","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s10549-017-4385-3","volume":"166","author":"D Kwapisz","year":"2017","unstructured":"Kwapisz D. Cyclin-dependent kinase 4\/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib. Breast Cancer Res Treat. 2017;166(1):41\u201354. https:\/\/doi.org\/10.1007\/s10549-017-4385-3.","journal-title":"Breast Cancer Res Treat"},{"key":"814_CR51","doi-asserted-by":"publisher","first-page":"102086","DOI":"10.1016\/j.ctrv.2020.102086","volume":"90","author":"A Desnoyers","year":"2020","unstructured":"Desnoyers A, Nadler MB, Kumar V, Saleh R, Amir E. Comparison of treatment related adverse events of different Cyclin-dependent kinase 4\/6 inhibitors in metastatic breast cancer: a network meta-analysis. Cancer Treat Rev. 2020;90:102086. https:\/\/doi.org\/10.1016\/j.ctrv.2020.102086.","journal-title":"Cancer Treat Rev"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-022-00814-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-022-00814-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-022-00814-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T15:32:29Z","timestamp":1685201549000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-022-00814-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,19]]},"references-count":51,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["814"],"URL":"https:\/\/doi.org\/10.1007\/s10238-022-00814-3","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,19]]},"assertion":[{"value":"8 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None of the authors have conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}